Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Palvella Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $35.46M, up 137.7% year over year. For fiscal 2025 it was $22.84M, up 180.2% from the year before. Over ten years it grew 10.7% a year on average. The highest annual figure on record is $66.66M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.84M | +180.2% |
| FY2024 | Dec 31, 2024 | $8.15M | -7.3% |
| FY2023 | Dec 31, 2023 | $8.79M | -83.4% |
| FY2022 | Dec 31, 2022 | $52.98M | -20.5% |
| FY2021 | Dec 31, 2021 | $66.66M | +43.3% |
| FY2020 | Dec 31, 2020 | $46.53M | -15.4% |
| FY2019 | Dec 31, 2019 | $55.00M | +32.6% |
| FY2018 | Dec 31, 2018 | $41.49M | +86.2% |
| FY2017 | Dec 31, 2017 | $22.29M | +13.1% |
| FY2016 | Dec 31, 2016 | $19.70M | +138.9% |
| FY2015 | Dec 31, 2015 | $8.24M | +47.2% |
| FY2014 | Dec 31, 2014 | $5.60M | -40.5% |
| FY2013 | Dec 31, 2013 | $9.41M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.47M | +143.7% |
| Q1 FY2026 | Mar 31, 2026 | $9.33M | +129.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.12M | +180.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.53M | +105.2% |
| Q2 FY2025 | Jun 30, 2025 | $5.12M | +254.9% |
| Q1 FY2025 | Mar 31, 2025 | $4.07M | +314.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.54M | -42.9% |
| Q3 FY2024 | Sep 30, 2024 | $3.18M | -66.8% |
| Q2 FY2024 | Jun 30, 2024 | $1.44M | -89.9% |
| Q1 FY2024 | Mar 31, 2024 | $984.00K | -92.7% |
| Q4 FY2023 | Dec 31, 2023 | $4.45M | -66.7% |
| Q3 FY2023 | Sep 30, 2023 | $9.60M | -29.4% |
| Q2 FY2023 | Jun 30, 2023 | $14.33M | +19.9% |
| Q1 FY2023 | Mar 31, 2023 | $13.42M | -4.6% |
| Q4 FY2022 | Dec 31, 2022 | $13.38M | -12.9% |
| Q3 FY2022 | Sep 30, 2022 | $13.59M | -28.2% |
| Q2 FY2022 | Jun 30, 2022 | $11.95M | -24.4% |
| Q1 FY2022 | Mar 31, 2022 | $14.07M | -15.1% |
| Q4 FY2021 | Dec 31, 2021 | $15.36M | +44.6% |
| Q3 FY2021 | Sep 30, 2021 | $18.94M | +60.2% |
| Q2 FY2021 | Jun 30, 2021 | $15.80M | +39.4% |
| Q1 FY2021 | Mar 31, 2021 | $16.56M | +29.8% |
| Q4 FY2020 | Dec 31, 2020 | $10.62M | -24.8% |
| Q3 FY2020 | Sep 30, 2020 | $11.82M | -10.5% |
| Q2 FY2020 | Jun 30, 2020 | $11.33M | -15.3% |
| Q1 FY2020 | Mar 31, 2020 | $12.76M | -10.8% |
| Q4 FY2019 | Dec 31, 2019 | $14.12M | +8.6% |
| Q3 FY2019 | Sep 30, 2019 | $13.21M | +15.9% |
| Q2 FY2019 | Jun 30, 2019 | $13.37M | +46.1% |
| Q1 FY2019 | Mar 31, 2019 | $14.30M | +80.1% |
| Q4 FY2018 | Dec 31, 2018 | $13.00M | +146.6% |
| Q3 FY2018 | Sep 30, 2018 | $11.40M | +82.2% |
| Q2 FY2018 | Jun 30, 2018 | $9.16M | +69.7% |
| Q1 FY2018 | Mar 31, 2018 | $7.94M | +48.1% |
| Q4 FY2017 | Dec 31, 2017 | $5.27M | -23.8% |
| Q3 FY2017 | Sep 30, 2017 | $6.26M | +35.4% |
| Q2 FY2017 | Jun 30, 2017 | $5.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.92M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.62M | – |
See a number that looks wrong?